Benefits From and Barriers to Portable Detection of Gluten, Based on a Randomized Pilot Trial of Patients With Celiac Disease
Randi L Wolf, Peter H R Green, Anne R Lee, Norelle R Reilly, Patricia Zybert, Benjamin Lebwohl, Randi L Wolf, Peter H R Green, Anne R Lee, Norelle R Reilly, Patricia Zybert, Benjamin Lebwohl
Abstract
Research links diminished quality of life (QOL) to the challenges of a strict gluten-free diet (GFD), the only treatment for celiac disease (CD).1-4 This pilot study assessed the acceptability and feasibility of a portable gluten sensor device (Nima) to promote GFD adherence and QOL.
Trial registration: ClinicalTrials.gov NCT03321214.
Conflict of interest statement
Disclosures: RW, AL, NR, and PZ have no conflicts to disclose. PG serves on the Advisory board of ImmusanT, Cellimmune and ImmunogenX. BL serves as a consultant for Takeda and serves on the Advisory Board of Innovate Biopharmaceuticals. BL and PG are both unpaid members of Nima’s Scientific Advisory Board.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Figures
Source: PubMed